Kyowa Kirin looks for safety and efficacy benefits as it takes novel antithrombin to Phase III
This article was originally published in Scrip
Kyowa Hakko Kirin has begun a Japanese Phase III clinical trial with what it says is the first recombinant human antithrombin product engineered to be deficient in fucose, providing potential advantages over both the natural blood plasma-derived glycoprotein and other synthetic versions.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.